|
Objective: High blood pressure is one of the most common cardiovascular disease, hypertension, left ventricular hypertrophy a significant increase in the incidence of cardiovascular accident, is closely associated with cardiovascular disease morbidity and mortality, an important independent risk factor. Therefore, reversal of left ventricular hypertrophy has become an important goal in the treatment of hypertension. Irbesartan is an angiotensin II receptor antagonists, not only has a good antihypertensive effect and tolerability, but also effectively reverses left ventricular hypertrophy, and also take advantage of the price. This study aimed to unnecessary further confirmed by comparison with perindopril, irbesartan unique cardioprotective effect provides a new way for the treatment of high blood pressure, and improve the quality of life of hypertensive patients to avoid medical funds waste. Method: Select the light of our hospital from 2007 to 2008, met the inclusion criteria, left ventricular hypertrophy, 120 cases of patients with moderate hypertension, were randomly divided into two groups, namely Group A: E Beisha group, B group: perindopril group, each group of 60 people. A group given irbesartan tablets 150 mg / d, morning orally once; B group was treated with perindopril 4 mg / d, 1 oral morning. The medication a total of 12 months. The course of treatment is not used in combination with other antihypertensive drugs. Every two weeks to adjust the dose, blood pressure control target of ≤ 140/90mmHg. If the blood pressure is poorly controlled, double dose of irbesartan and perindopril. Week follow-up measurement of blood pressure, 4 weeks blood pressure is not up to quit the experiment. Medication before the medication after four weeks, 12 months, in accordance with international standards by hand requires detection sitting blood pressure. Repeat blood pressure three times and averaged. The day before the experiment and after 12 months do echocardiography the LVMI, experimental process appeared with experimental drug-related adverse reactions (eg, dizziness, headache, cough, etc.) and can not be tolerated and potassium, glucose, lipids, calculated according to the Devereux formula , enzymology appeared experimental discounting abnormal. Results: The two groups of patients after 12 months of treatment, a total of 114 people have completed the entire experiment. The results showed the two drugs antihypertensive effect of irbesartan blood pressure compliance rate of 87.93% (51/58), the perindopril the Plymouth group BP compliance rate of 89.29% (50/56), the antihypertensive efficacy of the two drugs statistically significant difference (P> 0.05); two groups LVMI (g / m to 2) than before treatment were significantly reduced, the difference was statistically significant (P <0.01), no statistically significant differences in the two drugs (P> 0.05). Conclusion: Irbesartan and Perindopril can not only reduce blood pressure but also can significantly reduce left ventricular hypertrophy, reduce the incidence of malignant arrhythmias and sudden cardiac death, heart protective effect, both quite effective.
|